|
|
|
 |
|
Dear Colleagues
Research is the driving force behind innovation. The concept of evidence based medicine is founded on the putting into practice the most striking results of clinical research.
The challenge in evidence based medicine is managing the transition from research, through to the practice of large scale trials and vice versa from the patient's bedside back to the researcher.
The majority of practitioners find it difficult to keep pace with the rapid rhythm of innovations in cardiovascular therapy. To date, there has been no event dedicated specifically to clinical trials in cardiovascular disease that brings together key decision makers, creators of clinical trial protocol, sponsors, investigators, regulatory authorities, clinical research associates, as well as cardiologists.
|
|
|
|
Endorsed by: |
|
|
|
|
|
 
|
|
|
|
|
|
With the participation of: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thank you to all CVCT Forum 2011 speakers and participants!
CVCT Forum 2012 will take place from 30 Nov - 01 Dec in Paris
Recorded 2011 Sessions are available for your viewing!
Click here to access the webcast
|
|
Why you should attend :
|
 |
|
Interview with Han-Na Kim
Attending the Global CardioVascular Clinical Trialists (CVCT) Forum for the first time in 2010, Han-Na Kim was not expecting such a communicative and high-level delegation.
|
|
 |
|
Interview with Angeles Alonso
In her highly charged day job, Dr Angeles Alonso is a senior consultant in the Cardiology Department at Madrid's Hospital Universitario Puerta de Hierro Majadanhonda, leading a group of clinical care ...
|
|
 |
|
Interview with Sydney Goldstein
Renowned cardiologist Sidney Goldstein of Detroit’s Henry Ford Hospital attends many conferences each year. Yet it is the broad representation of his peers that keeps him coming back to the Global CardioVascular Clinical Trialists Forum (CVCT), as he explained recently...
|
|
|
More info
|
|
|
|
More info
|
|
|
|
More info
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Interview with Yasser Khder
The pharmaceutical industry is often in the firing line for clinical trials, as conflicts of interest, accusations of skewed results and partial view can potentially damage company reputations. New rules are now being prepared that will shape the way ...
|
|
 |
|
Interview with David Gordon
Dr David Gordon is Special Assistant for Clinical Studies in the Division of Cardiovascular Sciences, the National Heart, Lung and Blood Institute (NHLBI), NIH, in Bethesda, Maryland. As an overseer of various ...
|
|
 |
|
Interview with Luis Ruilope
Incoming chair of the European Society of Cardiology’s Working Group on Pharmacology, Pr Luis Ruilope has attended CVCT Forum at least eight times. He has seen the conference develop since its early ...
|
|
|
More info
|
|
|
|
More info
|
|
|
|
More info
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Interview with Corine Bernaud
Since its inception, Astra Zeneca’s EU Medical Affairs Director Corine Bernaud has been a supporter of CVCT Forum. Here, she explains why. From the beginning, over 10 years ago, what I liked in this program ...
|
|
 |
|
Interview with Jeffrey Borer
Dr Jeffrey Borer, Chair of Medicine at SUNY Downstate, participated in CVCT in 2009. He views opportunities for continual learning and knowledge-sharing as critical to maintaining skills and providing expert treatment to patients.
|
|
 |
|
Interview with Atul Pathak
When he arrived at his second CVCT Forum in 2009, Toulouse-based Pr Atul Pathak had two important potential trials on his mind, directly related to his two panel discussions: - Clinical trials in ...
|
|
|
More info
|
|
|
|
More info
|
|
|
|
More info
|
|
|
